Use of complementary therapies in patients with Parkinson's disease in singapore
Identifieur interne : 001851 ( PascalFrancis/Checkpoint ); précédent : 001850; suivant : 001852Use of complementary therapies in patients with Parkinson's disease in singapore
Auteurs : Louis C. S. Tan [Singapour] ; Puay-Ngoh Lau [Singapour] ; Roland Dominic G. Jamora [Singapour] ; Edwin S. Y. Chan [Singapour]Source :
- Movement disorders [ 0885-3185 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
To determine the frequency and spectrum of complementary therapy (CT) use and its association with sociodemographic or disease-specific characteristics among Asian patients with Parkinson's disease (PD) in Singapore, we interviewed 159 patients using a structured questionnaire. Sixty-one percent (95% CI = 55-67) of participants used at least one type of CT for PD, of which the most common were traditional medicine, acupuncture, and vitamins/health supplements. Among CT users, 40% (95% CI = 32-48) subjectively reported some improvement of their symptoms. However, only 16% informed their physicians of their use of CT. Due to unequal follow-up times, a survival analysis approach was adopted for statistical analysis. The rate of starting CT use was 1.2/100 person months. At 3 years after PD diagnosis, 48% had started using CT. Among a subgroup of participants, those with a baseline Unified Parkinson's Disease Rating Scale motor score of more than 16 were 2.5 times more likely to use CT compared to those with a baseline score of 16 or less (P = 0.031; 95% CI = 1.1-5.8). CT use was not associated with age of onset of PD or other sociodemographic factors. The use of CT is high among Asian PD patients. Patients with more severe motor dysfunction at onset are more likely to use CT.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:06-0135501Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Use of complementary therapies in patients with Parkinson's disease in singapore</title>
<author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
<wicri:noRegion>Department of Neurology, National Neuroscience Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lau, Puay Ngoh" sort="Lau, Puay Ngoh" uniqKey="Lau P" first="Puay-Ngoh" last="Lau">Puay-Ngoh Lau</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Nursing Administration, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
<wicri:noRegion>Department of Nursing Administration, National Neuroscience Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jamora, Roland Dominic G" sort="Jamora, Roland Dominic G" uniqKey="Jamora R" first="Roland Dominic G." last="Jamora">Roland Dominic G. Jamora</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
<wicri:noRegion>Department of Neurology, National Neuroscience Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chan, Edwin S Y" sort="Chan, Edwin S Y" uniqKey="Chan E" first="Edwin S. Y." last="Chan">Edwin S. Y. Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Trials and Epidemiology Research Unit</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
<wicri:noRegion>Clinical Trials and Epidemiology Research Unit</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0135501</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0135501 INIST</idno>
<idno type="RBID">Pascal:06-0135501</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C81</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001040</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001851</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Use of complementary therapies in patients with Parkinson's disease in singapore</title>
<author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
<wicri:noRegion>Department of Neurology, National Neuroscience Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lau, Puay Ngoh" sort="Lau, Puay Ngoh" uniqKey="Lau P" first="Puay-Ngoh" last="Lau">Puay-Ngoh Lau</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Nursing Administration, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
<wicri:noRegion>Department of Nursing Administration, National Neuroscience Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jamora, Roland Dominic G" sort="Jamora, Roland Dominic G" uniqKey="Jamora R" first="Roland Dominic G." last="Jamora">Roland Dominic G. Jamora</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
<wicri:noRegion>Department of Neurology, National Neuroscience Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chan, Edwin S Y" sort="Chan, Edwin S Y" uniqKey="Chan E" first="Edwin S. Y." last="Chan">Edwin S. Y. Chan</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Trials and Epidemiology Research Unit</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
<wicri:noRegion>Clinical Trials and Epidemiology Research Unit</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acupuncture</term>
<term>Alternative medicine</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Singapore</term>
<term>Treatment</term>
<term>Vitamin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Singapour</term>
<term>Médecine parallèle</term>
<term>Acupuncture</term>
<term>Vitamine</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Singapour</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Vitamine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To determine the frequency and spectrum of complementary therapy (CT) use and its association with sociodemographic or disease-specific characteristics among Asian patients with Parkinson's disease (PD) in Singapore, we interviewed 159 patients using a structured questionnaire. Sixty-one percent (95% CI = 55-67) of participants used at least one type of CT for PD, of which the most common were traditional medicine, acupuncture, and vitamins/health supplements. Among CT users, 40% (95% CI = 32-48) subjectively reported some improvement of their symptoms. However, only 16% informed their physicians of their use of CT. Due to unequal follow-up times, a survival analysis approach was adopted for statistical analysis. The rate of starting CT use was 1.2/100 person months. At 3 years after PD diagnosis, 48% had started using CT. Among a subgroup of participants, those with a baseline Unified Parkinson's Disease Rating Scale motor score of more than 16 were 2.5 times more likely to use CT compared to those with a baseline score of 16 or less (P = 0.031; 95% CI = 1.1-5.8). CT use was not associated with age of onset of PD or other sociodemographic factors. The use of CT is high among Asian PD patients. Patients with more severe motor dysfunction at onset are more likely to use CT.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Use of complementary therapies in patients with Parkinson's disease in singapore</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TAN (Louis C. S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LAU (Puay-Ngoh)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>JAMORA (Roland Dominic G.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CHAN (Edwin S. Y.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Nursing Administration, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Clinical Trials and Epidemiology Research Unit</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>86-89</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000133169150150</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>6 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0135501</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>To determine the frequency and spectrum of complementary therapy (CT) use and its association with sociodemographic or disease-specific characteristics among Asian patients with Parkinson's disease (PD) in Singapore, we interviewed 159 patients using a structured questionnaire. Sixty-one percent (95% CI = 55-67) of participants used at least one type of CT for PD, of which the most common were traditional medicine, acupuncture, and vitamins/health supplements. Among CT users, 40% (95% CI = 32-48) subjectively reported some improvement of their symptoms. However, only 16% informed their physicians of their use of CT. Due to unequal follow-up times, a survival analysis approach was adopted for statistical analysis. The rate of starting CT use was 1.2/100 person months. At 3 years after PD diagnosis, 48% had started using CT. Among a subgroup of participants, those with a baseline Unified Parkinson's Disease Rating Scale motor score of more than 16 were 2.5 times more likely to use CT compared to those with a baseline score of 16 or less (P = 0.031; 95% CI = 1.1-5.8). CT use was not associated with age of onset of PD or other sociodemographic factors. The use of CT is high among Asian PD patients. Patients with more severe motor dysfunction at onset are more likely to use CT.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Singapour</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Singapore</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Singapur</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Médecine parallèle</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Alternative medicine</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Medicina alternativa</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Acupuncture</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Acupuncture</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Acupuntura</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Vitamine</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Vitamin</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Vitamina</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Asie</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>086</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Singapour</li>
</country>
</list>
<tree><country name="Singapour"><noRegion><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name>
</noRegion>
<name sortKey="Chan, Edwin S Y" sort="Chan, Edwin S Y" uniqKey="Chan E" first="Edwin S. Y." last="Chan">Edwin S. Y. Chan</name>
<name sortKey="Jamora, Roland Dominic G" sort="Jamora, Roland Dominic G" uniqKey="Jamora R" first="Roland Dominic G." last="Jamora">Roland Dominic G. Jamora</name>
<name sortKey="Lau, Puay Ngoh" sort="Lau, Puay Ngoh" uniqKey="Lau P" first="Puay-Ngoh" last="Lau">Puay-Ngoh Lau</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001851 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001851 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Checkpoint |type= RBID |clé= Pascal:06-0135501 |texte= Use of complementary therapies in patients with Parkinson's disease in singapore }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |